Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion;Repigmentierung durch calcineurininhibitoren unter okklusion bei prätibialer vitiligo

JDDG - Journal of the German Society of Dermatology

Volumn 6, Issue 5, 2008, Pages 383-385

  Hartmann, Anke ^a,b   Bröcker, Eva Bettina ^a   Hamm, Henning ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Calcineurin antagonists; Pimecrolimus; Repigmentation; Tacrolimus; Vitiligo

Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; POLYURETHAN; TACROLIMUS;

ADOLESCENT; ANAMNESIS; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYDROCOLLOID; SKIN PIGMENTATION; SKIN TINGLING; VITILIGO;

ADMINISTRATION, TOPICAL; ADOLESCENT; CALCINEURIN; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEG DERMATOSES; OCCLUSIVE DRESSINGS; REMISSION INDUCTION; SKIN PIGMENTATION; TACROLIMUS; TIBIA; TREATMENT OUTCOME; VITILIGO;

EID: 44049088881     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06455.x     Document Type: Article

References (14)

1. Hartmann A, Lurz C, Hamm H, Bröcker EB, Hofmann UB. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005 44 : 736 742.
2. Hartmann A, Bröcker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004 64 : 89 107.
3. Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, Caro I, Jaracz E, Rico MJ US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005 53 (Suppl 2 S186 194.
4. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003 139 : 581 585.
5. Coskun B, Saral Y, Turgut D. Topical 0. 05% clobetasol propionate versus 1 % pimecrolimus ointment in vitiligo. Eur J Dermatol 2005 15 : 88 91.
6. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004 51 : 52 61.
7. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006, 4 : 942 946.
8. Hartmann A, Termeer C, Broecker E-B, Hamm H. Tacrolimus-ointment (Protopic) 0. 1% in adult patients with vitiligo: results of a placebo-controlled 12-months prospective study. J Dtsch Dermatol Ges 2005 3 : 174.
9. Berardesca E, Vignoli GP, Fideli D, Maibach H. Effect of occlusive dressings on the stratum corneum water holding capacity. Am J Med Sci 1992 304 : 25 28.
10. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000 136 : 999 1006.
11. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998 139 : 992 996.
12. Schuppe HC, Homey B, Assmann T, Martens R, Ruzicka T. Topical tacrolimus for pyoderma gangrenosum. Lancet 1998 351 : 832.
13. Prograf 5 mg/ml. Astellas Pharma GmbH, Fachinformation, April 2006.
14. Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, Paul CF. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: A randomized, investigator-blind comparison. J Am Acad Dermatol 2005 53 : 602 609.